Rosiglitazone, 98%

Name: Rosiglitazone, 98% | 122320-73-4
Brand: J&K Chemical
SKU: JK142624_25_G
Price: 282.6 USD
Availability: OutOfStock

Cat. No JK142624_25_G

Vendor: J&K Chemical

Product Information

Product Name

Rosiglitazone, 98%

Brand Name

J&K

Product Number

142624

CAS

122320-73-4

Molecular Formula

C18H19N3O3S

Molecular Weight

357.43

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

77999

IUPAC Name

5-4-2-methyl(pyridin-2-yl)aminoethoxyphenylmethyl-1,3-thiazolidine-2,4-dione

InChI Key

YASAKCUCGLMORW-UHFFFAOYSA-N

SMILES

CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3

Properties

Melting Point

154 - 158

Safety Information

Storage Condition

Store at 2-8℃

References Data Source From Pubchem

The Potential Role of Antidiabetic Agents in Bipolar Disorder

Publication Name: Current Treatment Options in Psychiatry

Publication Date: 2026-03-03

DOI: 10.1007/s40501-026-00375-2

Ulcerative colitis, pathophysiological mechanisms and drug repurposing: a new therapeutic dawn-narrative review

Publication Name: Inflammopharmacology

Publication Date: 2026-03-02

DOI: 10.1007/s10787-025-02101-5

Development of a next-generation closed-loop precision system: multiscale-engineered nanocomposite hydrogel microneedles

Publication Name: Bio-Design and Manufacturing

Publication Date: 2026-03

DOI: 10.1631/bdm.2500275

Advancement in peptide-based therapeutics for the treatment of type 2 diabetes mellitus: current progress and future prospects

Publication Name: Molecular Diversity

Publication Date: 2026-02-26

DOI: 10.1007/s11030-025-11455-5

Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy – an analysis of Swiss pharmacovigilance data

Publication Name: European Journal of Clinical Pharmacology

Publication Date: 2026-02-24

DOI: 10.1007/s00228-025-03968-7

Rosiglitazone, 98%

Product Information

General Information

Properties

Safety Information

References Data Source From Pubchem

The Potential Role of Antidiabetic Agents in Bipolar Disorder

Ulcerative colitis, pathophysiological mechanisms and drug repurposing: a new therapeutic dawn-narrative review

Development of a next-generation closed-loop precision system: multiscale-engineered nanocomposite hydrogel microneedles

Advancement in peptide-based therapeutics for the treatment of type 2 diabetes mellitus: current progress and future prospects

Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy – an analysis of Swiss pharmacovigilance data